GSK Plc ( NYSE: GSK ) shares traded in the green on Wednesday, snapping six straight days of losses. The stock closed up 0.65% at $38.
46. GSK has gained 9% in the last 12 months and fallen 7% in the last one month. YTD, the stock has trailed compared to the broader S&P 500 market, which rose 15.
5%, vs the company’s gain of 3.10%. Looking at Seeking Alpha's Quant Ratings, this UK-based company has Hold rating with a score of 3.
14 out of 5. When it comes to Wall Street analysis, 4 out of 8 analysts recommend a Hold, 2 rate it as a Strong Buy, 1 rates it as a Buy, 1 rates it as Sell. According to Allka Research, “From a global perspective, an additional key factor that will accelerate the growth of GSK's operating income and revenue is an increase in its R&D spending.
” Seeking Alpha analysts have a Buy rating on the company. More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript CureVac to cut 30% of workforce as GSK buys rights to make flu, covid shots GSK, Pfizer decline as CDC advisors recommend narrower age range for RSV shots.